Allarity considers partnerships for the potential launch of cancer drug

Within 12 months, Allarity Therapeutics will hopefully know whether cancer drug dovitinib has been approved by the FDA in the US. Subsequent marketing efforts might happen with a partner, says CEO Steve Carchedi.

Steve Carchedi, CEO at Allarity Therapeutics | Photo: Allarity Therapeutics / PR

After several years of preparation, one of Allarity Therapeutics’ biggest days came along shortly before Christmas, when the firm could submit for approval its drug, dovitinib, against kidney cancer to the US Food and Drug Administration (FDA).

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs